Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer

BackgroundThe emergence of HER2 antibody-drug conjugates provides new treatment decisions for breast cancer patients, especially those with HER2-low expression. In order to explore the biological characteristics of breast cancer with HER2-low expression, the HER2-low category in primary breast cance...

Full description

Bibliographic Details
Main Authors: Jiuyan Shang, Xuemei Sun, Zihang Xu, Lijing Cai, Chang Liu, Si Wu, Yueping Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
breast cancer
human epidermal growth factor receptor 2
hormone receptor
neoadjuvant therapy
pathological complete response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1086480/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1086480/full

Similar Items